<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982968</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00049804</org_study_id>
    <secondary_id>1UM1HL119089</secondary_id>
    <nct_id>NCT01982968</nct_id>
  </id_info>
  <brief_title>Treatment of IPF With Laparoscopic Anti-Reflux Surgery</brief_title>
  <acronym>WRAP-IPF</acronym>
  <official_title>Weighing Risks and Benefits of Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in&#xD;
      subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER)&#xD;
      will slow the decline of forced vital capacity (FVC) over 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol proposes to test the following hypothesis: Treatment with laparoscopic&#xD;
      anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal&#xD;
      gastroesophageal (GER) reflux will slow the decline of forced vital capacity (FVC) over 48&#xD;
      weeks. This study will randomize approximately 58 subjects with IPF and abnormal acid reflux&#xD;
      on 24-hour impedance / pH monitoring to laparoscopic anti-reflux surgery or standard care&#xD;
      (randomization ratio 1:1). Subjects will be followed for 48 weeks or until the time of lung&#xD;
      transplantation or death.&#xD;
&#xD;
      We aim to achieve the following: determine the impact of laparoscopic anti-reflux surgery on&#xD;
      change in FVC over 48 weeks in patients with IPF and abnormal GER; correlate the reduction in&#xD;
      acid and non-acid reflux events with the change in FVC over 48 weeks in patients with IPF and&#xD;
      abnormal GER; determine the safety of laparoscopic anti-reflux surgery in patients with IPF&#xD;
      and abnormal GER; explore the impact of laparoscopic anti-reflux surgery on key secondary&#xD;
      endpoints over 48 weeks in patients with IPF and abnormal GER; identify molecular markers of&#xD;
      IPF disease activity and gastroesophageal reflux in biological samples from patients with IPF&#xD;
      and abnormal GER.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in FVC (in liters) between enrollment and 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Score From Baseline for Acid and Non-acid Reflux Events at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in acid and non-acid reflux events from baseline to week 48. All subjects answered questions related to their reflux using a Likert scale (0 = never, 1 =occasionally, 2 = sometimes, 3 = often, 4 = always).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Laparoscopic Anti-reflux Surgery</measure>
    <time_frame>48 weeks</time_frame>
    <description>Overall safety of laparoscopic anti-reflux surgery in patients with IPF and abnormal GER as measured by number of participants who experienced death, serious adverse event, or other (not including serious) adverse event. See Adverse Events section for additional details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>48 weeks</time_frame>
    <description>Impact of anti-reflux surgery on all-cause mortality from enrollment to 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-elective Hospitalization</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Impact on non-elective hospitalizations from baseline to 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbations</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Impact on acute exacerbations of IPF from baseline to week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOQB) Score</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in UCSD SOQB score from baseline to week 48. The score range is 0-120. Higher scores indicate higher breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Score</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in SGRQ score from baseline to week 48. The score range is 0-100. Higher scores indicate more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute Walk Distance</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in 6-minute walk distance from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in VAS from baseline to week 48. The scale range is 1-100. Lower scores indicate no cough and 100 indicates the worst cough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Resolution CT (HRCT) Fibrosis Score.</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change in HRCT fibrosis score from baseline to week 48. HRCT Fibrosis score is calculated as a percentage. Higher percentage indicates more fibrosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive laparoscopic fundoplication surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Full fundoplication surgery for the treatment of abnormal GER</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>Nissen fundoplication</other_name>
    <other_name>Laparoscopic fundoplication</other_name>
    <other_name>Laparoscopic anti-reflux surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  Abnormal GER on 24-hour pH monitoring (DeMeester score &gt; 14.7)&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Willing to undergo laparoscopic anti-reflux surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FVC &lt; 50% predicted&#xD;
&#xD;
          -  FEV1/FVC ratio &lt; 0.65&#xD;
&#xD;
          -  Resting room air PaO2 &lt; 60mm Hg&#xD;
&#xD;
          -  Unable to walk 50 meters on 6 minute walk test&#xD;
&#xD;
          -  Acute respiratory illness in last 12 weeks&#xD;
&#xD;
          -  Experimental medication for IPF in last 28 days&#xD;
&#xD;
          -  Listed for lung transplantation at screening&#xD;
&#xD;
          -  Unable to safely undergo surgery&#xD;
&#xD;
          -  History of esophageal / bariatric / gastric surgery&#xD;
&#xD;
          -  History of cancer (other than non-melanoma skin cancer) in last 3 years&#xD;
&#xD;
          -  Pregnant at time of screening or enrollment&#xD;
&#xD;
          -  Unable to obtain pre-authorized approval from a third party payer for surgery and&#xD;
             related costs&#xD;
&#xD;
          -  Life expectancy &lt; 48 weeks due to another illness&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Known severe pulmonary hypertension (mean pressure &gt; 35 mm Jg on RHC; RVSP &gt; 50 mm Hg&#xD;
             on ECHO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold R Collard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ganesh Raghu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin J Anstrom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018 Sep;6(9):707-714. doi: 10.1016/S2213-2600(18)30301-1. Epub 2018 Aug 9.</citation>
    <PMID>30100404</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>IPF</keyword>
  <keyword>Gastroesophageal reflux</keyword>
  <keyword>GER</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01982968/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01982968/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
        </group>
        <group group_id="P2">
          <title>Surgery</title>
          <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal GER</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
        </group>
        <group group_id="B2">
          <title>Surgery</title>
          <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal GER</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="7.35"/>
                    <measurement group_id="B2" value="70.6" spread="5.97"/>
                    <measurement group_id="B3" value="69.9" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Change in FVC (in liters) between enrollment and 48 weeks.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>Randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Change in FVC (in liters) between enrollment and 48 weeks.</description>
          <population>Randomized patients</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" lower_limit="-.23" upper_limit="-.02"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.15" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score From Baseline for Acid and Non-acid Reflux Events at 48 Weeks</title>
        <description>Change in acid and non-acid reflux events from baseline to week 48. All subjects answered questions related to their reflux using a Likert scale (0 = never, 1 =occasionally, 2 = sometimes, 3 = often, 4 = always).</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score From Baseline for Acid and Non-acid Reflux Events at 48 Weeks</title>
          <description>Change in acid and non-acid reflux events from baseline to week 48. All subjects answered questions related to their reflux using a Likert scale (0 = never, 1 =occasionally, 2 = sometimes, 3 = often, 4 = always).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Do you get heartburn?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="1.09"/>
                    <measurement group_id="O2" value="-1.04" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does your stomach get bloated?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.82"/>
                    <measurement group_id="O2" value="-0.39" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do you get bitter liquid (acid) in throat?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="1.01"/>
                    <measurement group_id="O2" value="-1.13" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do you burp a lot?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.72"/>
                    <measurement group_id="O2" value="-0.74" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Laparoscopic Anti-reflux Surgery</title>
        <description>Overall safety of laparoscopic anti-reflux surgery in patients with IPF and abnormal GER as measured by number of participants who experienced death, serious adverse event, or other (not including serious) adverse event. See Adverse Events section for additional details.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Laparoscopic Anti-reflux Surgery</title>
          <description>Overall safety of laparoscopic anti-reflux surgery in patients with IPF and abnormal GER as measured by number of participants who experienced death, serious adverse event, or other (not including serious) adverse event. See Adverse Events section for additional details.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Not Including Serious) Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>Impact of anti-reflux surgery on all-cause mortality from enrollment to 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>Impact of anti-reflux surgery on all-cause mortality from enrollment to 48 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-elective Hospitalization</title>
        <description>Impact on non-elective hospitalizations from baseline to 48 weeks.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-elective Hospitalization</title>
          <description>Impact on non-elective hospitalizations from baseline to 48 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Exacerbations</title>
        <description>Impact on acute exacerbations of IPF from baseline to week 48.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Exacerbations</title>
          <description>Impact on acute exacerbations of IPF from baseline to week 48.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOQB) Score</title>
        <description>Change in UCSD SOQB score from baseline to week 48. The score range is 0-120. Higher scores indicate higher breathlessness.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOQB) Score</title>
          <description>Change in UCSD SOQB score from baseline to week 48. The score range is 0-120. Higher scores indicate higher breathlessness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="-6.24" upper_limit="4.86"/>
                    <measurement group_id="O2" value="0.71" lower_limit="-5.62" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
        <description>Change in SGRQ score from baseline to week 48. The score range is 0-100. Higher scores indicate more limitations.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
          <description>Change in SGRQ score from baseline to week 48. The score range is 0-100. Higher scores indicate more limitations.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" lower_limit="-8.35" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.04" lower_limit="-3.66" upper_limit="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-minute Walk Distance</title>
        <description>Change in 6-minute walk distance from baseline to week 48</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>6-minute Walk Distance</title>
          <description>Change in 6-minute walk distance from baseline to week 48</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" lower_limit="-14.77" upper_limit="33.02"/>
                    <measurement group_id="O2" value="16.54" lower_limit="-4.80" upper_limit="37.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough Visual Analog Scale (VAS)</title>
        <description>Change in VAS from baseline to week 48. The scale range is 1-100. Lower scores indicate no cough and 100 indicates the worst cough.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>Cough Visual Analog Scale (VAS)</title>
          <description>Change in VAS from baseline to week 48. The scale range is 1-100. Lower scores indicate no cough and 100 indicates the worst cough.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" lower_limit="-2.01" upper_limit="16.31"/>
                    <measurement group_id="O2" value="4.74" lower_limit="-3.14" upper_limit="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-Resolution CT (HRCT) Fibrosis Score.</title>
        <description>Change in HRCT fibrosis score from baseline to week 48. HRCT Fibrosis score is calculated as a percentage. Higher percentage indicates more fibrosis.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Data are not available to be reported due to inability to obtain imaging data on participants and generate a score.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal Gastroesophageal reflux (GER)</description>
          </group>
        </group_list>
        <measure>
          <title>High-Resolution CT (HRCT) Fibrosis Score.</title>
          <description>Change in HRCT fibrosis score from baseline to week 48. HRCT Fibrosis score is calculated as a percentage. Higher percentage indicates more fibrosis.</description>
          <population>Data are not available to be reported due to inability to obtain imaging data on participants and generate a score.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Subjects to receive standard anti-reflux treatment per clinical discretion</description>
        </group>
        <group group_id="E2">
          <title>Surgery</title>
          <description>Subjects will receive laparoscopic fundoplication surgery&#xD;
Surgery: Full fundoplication surgery for the treatment of abnormal GER</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal haemorrhave</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>cholecytitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Worsening</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>incision site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harold Collard, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415 4761000</phone>
      <email>Harold.Collard@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

